Alterity Therapeutics (ATHE) EBITDA (2009 - 2024)

Alterity Therapeutics' EBITDA history runs 9 years deep, the most recent figure standing at -$12.8 million for Q2 2024.

• On a quarterly basis, EBITDA fell 36.64% year-over-year to -$12.8 million in Q2 2024; TTM through Jun 2024 was -$35.3 million, a 12.56% decrease from a year earlier, with the FY2025 full-year figure at -$7.8 million, up 39.02% from the prior year.
• EBITDA declined to -$12.8 million in Q2 2024 per ATHE's latest filing, from -$9.3 million in the prior quarter.
• Across five years, EBITDA topped out at -$9.3 million in Q2 2022 and bottomed at -$12.8 million in Q2 2024.
• The 3-year median for EBITDA is -$9.3 million (2023), against an average of -$10.5 million.
• Across the five-year window, EBITDA fell 0.1% in 2023 and tumbled 36.64% in 2024, its largest moves.
• Year by year, EBITDA stood at -$9.3 million in 2022, then slipped by 0.1% to -$9.3 million in 2023, then tumbled by 36.64% to -$12.8 million in 2024.
• Per Business Quant, the three latest ATHE EBITDA figures stand at -$12.8 million (Q2 2024), -$9.3 million (Q2 2023), and -$9.3 million (Q2 2022).